• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

直肠癌的多模态治疗。

Multimodal Treatment of Rectal Cancer.

机构信息

Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen; Department of Radiotherapy and Oncology, Goethe University Frankfurt am Main; Department of Medical Hematology and Oncology, University Hospital Mannheim, University of Heidelberg.

出版信息

Dtsch Arztebl Int. 2022 Aug 22;119(33-34):570-580. doi: 10.3238/arztebl.m2022.0254.

DOI:10.3238/arztebl.m2022.0254
PMID:35791271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9743213/
Abstract

BACKGROUND

Colorectal cancer is one of the three most common types of cancer in Germany. Approximately 30% of these cancers are located in the rectum, corresponding to about 18 000 new cases per year.

METHODS

This review is based on publications retrieved by a selective search in the PubMed database, including current guidelines and recommendations.

RESULTS

Specialized imaging, particularly magnetic resonance imaging, is essential for treatment planning. In very early stages of this disease, tumors without risk factors can be excised locally. Otherwise, radical surgical resection with lymphadenectomy remains the standard treatment, and can be performed either minimally invasive or open. At present, neoadjuvant treatment plans are evolving in the direction of total neoadjuvant therapy. In addition, recent studies investigate whether the improved efficacy of neoadjuvant therapy might now enable patients with a complete clinical remission to be spared from surgical resection (organ-preserving watch-and-wait strategy).

CONCLUSION

The treatment of rectal cancer is a prime example of an interdisciplinary, multimodal approach. In the past, the focus was mainly on improving oncologic outcomes; at present, increasing attention is being devoted to the patients' quality of life as well and the functional aspects of the various modes of treatment.

摘要

背景

在德国,结直肠癌是最常见的三种癌症之一。这些癌症中约有 30%位于直肠,每年约有 18000 例新发病例。

方法

本综述基于在 PubMed 数据库中进行选择性搜索获得的出版物,包括当前的指南和建议。

结果

专门的影像学检查,特别是磁共振成像,对治疗计划至关重要。在疾病的早期阶段,没有风险因素的肿瘤可以局部切除。否则,根治性手术切除伴淋巴结清扫仍然是标准治疗方法,可以采用微创或开放性手术进行。目前,新辅助治疗方案正在朝着完全新辅助治疗的方向发展。此外,最近的研究探讨了新辅助治疗的疗效提高是否可以使完全临床缓解的患者免于手术切除(保留器官的观察等待策略)。

结论

直肠癌的治疗是一个典型的多学科、多模式的方法。过去,主要重点是提高肿瘤学治疗效果;目前,越来越关注患者的生活质量以及各种治疗方式的功能方面。

相似文献

1
Multimodal Treatment of Rectal Cancer.直肠癌的多模态治疗。
Dtsch Arztebl Int. 2022 Aug 22;119(33-34):570-580. doi: 10.3238/arztebl.m2022.0254.
2
Is Nonoperative Management of Rectal Cancer Feasible?直肠癌的非手术治疗是否可行?
Adv Surg. 2023 Sep;57(1):141-154. doi: 10.1016/j.yasu.2023.05.001. Epub 2023 Jun 14.
3
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].巩固性新辅助治疗或全新辅助治疗后低位直肠癌的保直肠手术:初步报告
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
4
[Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy].[局部进展期中低位直肠癌新辅助治疗后完全缓解的合理评估:“观察等待”策略的利弊]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jun 25;22(6):507-513. doi: 10.3760/cma.j.issn.1671-0274.2019.06.002.
5
A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.局部直肠癌放化疗后完全临床缓解者观察等待的纵向队列研究:研究方案。
BMC Cancer. 2022 Mar 1;22(1):222. doi: 10.1186/s12885-022-09304-x.
6
["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].直肠癌新辅助治疗后的“观察与等待”策略:中国外科医生的认知、态度及治疗选择现状调查
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jun 25;22(6):550-559. doi: 10.3760/cma.j.issn.1671-0274.2019.06.008.
7
[Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].[新辅助放化疗后直肠癌的观察等待策略或器官保留结果:来自单一癌症中心的35例报告]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Apr 25;20(4):417-424.
8
Nonoperative Management of Rectal Cancer: The Watch and Wait Strategy.直肠癌的非手术治疗:观察与等待策略。
Surg Oncol Clin N Am. 2022 Apr;31(2):171-182. doi: 10.1016/j.soc.2021.11.003. Epub 2022 Mar 9.
9
[Advances of optimized neoadjuvant therapy in the treatment of locally advanced rectal cancer].[优化新辅助治疗在局部晚期直肠癌治疗中的进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Jun 25;22(6):527-533. doi: 10.3760/cma.j.issn.1671-0274.2019.06.005.
10
Salvage Surgery With Organ Preservation for Patients With Local Regrowth After Watch and Wait: Is It Still Possible?观察等待后局部复发生存患者行保留器官的挽救性手术:是否可行?
Dis Colon Rectum. 2020 Aug;63(8):1053-1062. doi: 10.1097/DCR.0000000000001707.

引用本文的文献

1
Prognostic and Predictive Value of Pan-Immune Inflammation Value in Rectal Cancer Patients Treated With Neoadjuvant Therapy.新辅助治疗的直肠癌患者全免疫炎症值的预后及预测价值
Cancer Control. 2025 Jan-Dec;32:10732748251361684. doi: 10.1177/10732748251361684. Epub 2025 Jul 15.
2
Education and Symptom Reporting in an mHealth App for Patients With Cancer: Mixed Methods Development and Validation Study.一款针对癌症患者的移动健康应用程序中的教育与症状报告:混合方法开发与验证研究
JMIR Hum Factors. 2025 Apr 28;12:e60169. doi: 10.2196/60169.
3
Prognostic Value of Separate Extramural Vascular Invasion Reporting in Operative Samples of Rectal Cancer: Single-Institutional Experience.直肠癌手术样本中单独报告壁外血管侵犯的预后价值:单机构经验
Cancers (Basel). 2024 Oct 24;16(21):3579. doi: 10.3390/cancers16213579.
4
Change in Quality of Life in Patients with Advanced Rectal Cancer Between 2010 and 2022.2010年至2022年间晚期直肠癌患者生活质量的变化
Healthcare (Basel). 2024 Oct 23;12(21):2108. doi: 10.3390/healthcare12212108.
5
Immunotherapy for colorectal cancer.结直肠癌的免疫治疗。
Front Immunol. 2024 Aug 21;15:1433315. doi: 10.3389/fimmu.2024.1433315. eCollection 2024.
6
[A 5-year follow-up of the RAPIDO trial: Back to the future of long-course radiochemotherapy in total neoadjuvant treatment (TNT) for locally advanced rectal cancer?].[RAPIDO试验的5年随访:局部晚期直肠癌全新辅助治疗(TNT)中长程放化疗的未来回归?]
Strahlenther Onkol. 2024 Jul;200(7):649-651. doi: 10.1007/s00066-024-02232-8. Epub 2024 Apr 22.
7
Elderly Rectal Cancer: An Updated Review.老年直肠癌:最新综述。
Curr Oncol Rep. 2024 Feb;26(2):181-190. doi: 10.1007/s11912-024-01495-9. Epub 2024 Jan 25.
8
Prognostic value of the ratio of pretreatment carcinoembryonic antigen to tumor volume in rectal cancer.直肠癌治疗前癌胚抗原与肿瘤体积比值的预后价值
J Gastrointest Oncol. 2023 Dec 31;14(6):2395-2408. doi: 10.21037/jgo-23-683. Epub 2023 Dec 27.
9
Impact of COVID-19 on Quality of Life in Long-Term Advanced Rectal Cancer Survivors.新冠疫情对长期晚期直肠癌幸存者生活质量的影响。
Healthcare (Basel). 2023 Jul 8;11(14):1981. doi: 10.3390/healthcare11141981.

本文引用的文献

1
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.直肠癌患者接受全新辅助治疗后的器官保存。
J Clin Oncol. 2022 Aug 10;40(23):2546-2556. doi: 10.1200/JCO.22.00032. Epub 2022 Apr 28.
2
Increasing Incidence of Early-Onset Colorectal Cancer.早发性结直肠癌发病率上升。
N Engl J Med. 2022 Apr 21;386(16):1547-1558. doi: 10.1056/NEJMra2200869.
3
Selection of patients with rectal cancer for neoadjuvant therapy using pre-therapeutic MRI - Results from OCUM trial.使用治疗前 MRI 对直肠癌患者进行新辅助治疗的选择 - OCUM 试验的结果。
Eur J Radiol. 2022 Feb;147:110113. doi: 10.1016/j.ejrad.2021.110113. Epub 2021 Dec 28.
4
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
5
[Complete response after neoadjuvant therapy of rectal cancer: implications for surgery].[直肠癌新辅助治疗后的完全缓解:对手术的影响]
Chirurg. 2022 Feb;93(2):144-151. doi: 10.1007/s00104-021-01540-4. Epub 2021 Dec 8.
6
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.放化疗联合诱导或巩固化疗作为局部晚期直肠癌患者的全新辅助治疗:CAO/ARO/AIO-12 随机临床试验的长期结果。
JAMA Oncol. 2022 Jan 1;8(1):e215445. doi: 10.1001/jamaoncol.2021.5445. Epub 2022 Jan 20.
7
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer.国际共识推荐意见:直肠癌患者接受(放)化疗后器官保存的关键结局指标
Nat Rev Clin Oncol. 2021 Dec;18(12):805-816. doi: 10.1038/s41571-021-00538-5. Epub 2021 Aug 4.
8
Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients.用于预测直肠癌患者新辅助治疗结果的生物标志物和基于细胞的模型。
Biomark Res. 2021 Jul 28;9(1):60. doi: 10.1186/s40364-021-00313-9.
9
[Standardization of preoperative locoregional staging in rectal cancer with MRI].[直肠癌术前局部区域分期的MRI标准化]
Chirurg. 2021 May;92(5):482-484. doi: 10.1007/s00104-021-01411-y. Epub 2021 Apr 28.
10
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial.新辅助放化疗后中低位直肠癌的开腹与腹腔镜手术比较(COREAN 试验):一项开放标签、非劣效性、随机对照试验的 10 年随访。
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):569-577. doi: 10.1016/S2468-1253(21)00094-7. Epub 2021 Apr 23.